Predicting progression to AML
Nat Med
.
2018 Jul;24(7):904-906.
doi: 10.1038/s41591-018-0114-7.
Authors
Rob S Sellar
1
2
3
,
Siddhartha Jaiswal
4
,
Benjamin L Ebert
5
6
7
Affiliations
1
Brigham and Women's Hospital, Boston, MA, USA.
2
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
3
UCL Cancer Institute, University College London, London, UK.
4
Department of Pathology, Stanford University, Stanford, CA, USA.
5
Brigham and Women's Hospital, Boston, MA, USA. bebert@partners.org.
6
Broad Institute of MIT and Harvard, Cambridge, MA, USA. bebert@partners.org.
7
Dana-Farber Cancer Institute, Boston, MA, USA. bebert@partners.org.
PMID:
29988142
DOI:
10.1038/s41591-018-0114-7
No abstract available
Publication types
Comment
MeSH terms
Disease Progression
Humans
Leukemia, Myeloid, Acute*
Grants and funding
P01 CA066996/CA/NCI NIH HHS/United States
R01 HL082945/HL/NHLBI NIH HHS/United States